Jump to content



Recommended Posts

  • Replies 10k
  • Created
  • Last Reply

Top Posters In This Topic

Top Posters In This Topic

Posted Images



the PR on 16th Dec explains why they pulled a divisional patent about to be issued ('841).

That being, in light of the BPAI decision on '099, this '841 patent was over reduced in it's claims

so examiner would allow it - but in the nick of time they got the BPAI decision on '099, and can

now use this to re-expand the claims of '841. Likewise they'll use it for other pending divisional

patents too.


The new claims of '099 I think are just to wrap up '099 via the re-exam, ie: claims stated to the

satisfaction of the USPTO (examiner) for allowance, in light of the judges decision.

Link to comment
Share on other sites

the following summary from Rossi's paper in 2009 "The promises and pitfalls of RNA-interference-based therapeutics", quite

as you'd expect (cause he's a smart dude) still rings truer than recent media crap on the so called downfall of RNAi



Gazing ahead

Despite the technique's youth, the list of diseases for which RNAi is being tested as a therapeutic agent is extensive, and includes Parkinson's disease, Lou Gehrig's disease, HIV infection, wet age-related macular degeneration, type 2 diabetes, obesity, hypercholesterolaemia, rheumatoid arthritis, respiratory diseases and cancers.


It is already a multimillion dollar business, projected to reach US$1 billion by 2010, and intellectual property rights will become an increasingly important concern in the coming years.


However, although much has been accomplished, obstacles remain that will hamper the race to the clinic. The ultimate goal of achieving RNAi-based therapies for life-threatening or debilitating diseases cannot be attained without improving the safety, effectiveness and reliability of RNAi-trigger delivery systems. The use of targeted delivery strategies that permit systemic delivery will be a big step towards fulfilling this difficult task.


The development of new, noninvasive imaging methods to monitor the in vivo delivery of siRNAs, such as labelling with near-infrared dyes95, will aid studies of tissue uptake and biodistribution.


Although RNAi is not yet an accepted therapeutic modality, the enormous interest in this phenomenon ensures that we will soon witness fast advances and new applications for RNAi-based therapies.


Given the way that RNAi has transformed basic research and the unprecedented speed with which it has reached the clinic, the coming years promise to be exciting.

Link to comment
Share on other sites

not a chance with La Jolla sitting on the clutch


I thought they where sitting behind the stearing wheel. La Jolla aint as bad as they are made out to be, they work for us and when we say jump they will say how high !!! What is the interest rates in the us again ?

Link to comment
Share on other sites

RXi on a bolter last couple of days. PFE has been associated with them. Is this the end?


Through a process of M&A I easily see five GENZ' being created around those ALNY options. If you look closely at the GENZ deal and seperate out the CVR part as a stand alone transaction then it was all about Mipo (antisense) and IP. Interestingly there has been no word on the deal from ISIS.

Link to comment
Share on other sites

A good read with The Hauss even getting a mention. Also the New York Times article on the demise of RNAi.


Go down the page under the heading as below.


PfizerÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s exit from RNAi and regenerative medicine: the issue of technological prematurity





Link to comment
Share on other sites

Are you seeing a connx between this deal and further deals involving BLT?


Genzyme is a classic biotech. They started life creating orphan drugs for metabolic disease. The fact than Sanofi has made this purchase is significant in two ways: 1) it makes a break from the "top line" revenue consolidation of BigPharma; and 2) it signals renewed M&A activity, by BigPharma, for pipeline biotech.


What we need for a BLT transaction is a restored, active, M&A environment - the Genzyme deal signals "spring time for M&A".


Rekindling RNAi interest is the second element - and I am much heartened by Dirk's recent blog on the Silence solid tumour compound. It is only a matter of time before BigPharma's oligoneuronal attitude to oligonucleotide drugs - changes.


Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

  • Create New...